CEBPB antisense RNA 1 (CEBPB-AS1)

CEBPB antisense RNA 1 (CEBPB-AS1) is a long non-coding RNA (lncRNA) that partially overlaps the CEBPB gene in an antisense, head-to-head orientation[1][4]. It is a polyadenylated and stable transcript present in both the nucleus and cytoplasm[1]. CEBPB-AS1 plays a regulatory role in the expression of CEBPB, a transcription factor, by participating in epigenetic modifications and chromatin remodeling at the CEBPB promoter, largely through interactions with the chromatin-associated protein CTCF[1]. Silencing of CEBPB-AS1 increases CEBPB expression and sensitizes melanoma cells, including those resistant to BRAF inhibitors suchs as vemurafenib, to drug-induced apoptosis, suggesting its potential as a therapeutic modulator and biomarker in melanoma treatment[1][3]. CEBPB-AS1 represents one of many lncRNAs implicated in fine-tuning gene regulation in cancer biology, particularly related to therapy resistance[1].

Other names

CEBPB-AS1CEBPB Antisense RNA 1[4]ENSG00000277449NCBI Gene: 101927559HGNC: 51226[4]

Silencing CEBPB-AS1 results in upregulation of CEBPB, enhanced CEBPB binding to DNA, and increased sensitivity of melanoma cells to BRAF inhibitors such as vemurafenib[1][3]. CEBPB-AS1 may serve as a scaffold for chromatin-modifying proteins (CTCF), modulating chromatin accessibility of the CEBPB promoter and thereby influencing CEBPB transcription[1].